Summary

Several new agents are being explored for the management of heart failure (HF), which target different pathways involved in this complex disease. This article discusses human stresscopin, as well as a review of neurohumoral modulation, potential advantages of biased ligand at the angiotensin II type 1 receptor, soluble guanylate cyclase (sGC) stimulators, and potassium-binding polymers in HF.